IFIH1 and interstitial lung disease: One study by Janardana et al. showed that a 0.5 g + 0.5 g rituximab regimen (2 weeks apart) had a similar effect to the 1 g + 1 g regimen.23 Mao et al. used an ultra-low dose of rituximab (100 mg) as an add-on therapy for patients with anti-MDA5-positive interstitial lung disease (ILD), resulting in persistent B-cell depletion that lasted 180 days, and may decrease mortality.24